Literature DB >> 22424656

Hydroxocobalamin and epinephrine both improve survival in a swine model of cyanide-induced cardiac arrest.

Vikhyat S Bebarta1, Rebecca L Pitotti, Patricia S Dixon, Sandra Valtier, Luis Esquivel, Anneke Bush, Charles M Little.   

Abstract

STUDY
OBJECTIVE: To determine whether hydroxocobalamin will improve survival compared with epinephrine and saline solution controls in a model of cyanide-induced cardiac arrest.
METHODS: Forty-five swine (38 to 42 kg) were tracheally intubated, anesthetized, and central venous and arterial continuous cardiovascular monitoring catheters were inserted. Potassium cyanide was infused until cardiac arrest developed, defined as mean arterial pressure less than 30 mm Hg. Animals were treated with standardized mechanical chest compressions and were randomly assigned to receive one of 3 intravenous bolus therapies: hydroxocobalamin, epinephrine, or saline solution (control). All animals were monitored for 60 minutes after cardiac arrest. Additional epinephrine infusions were used in all arms of the study after return of spontaneous circulation for systolic blood pressure less than 90 mm Hg. A sample size of 15 animals per group was determined according to a power of 80%, a survival difference of 0.5, and an α of 0.05. Repeated-measure ANOVA was used to determine statistically significant changes between groups over time.
RESULTS: Baseline weight, time to arrest, and cyanide dose at cardiac arrest were similar in the 3 groups. Coronary perfusion pressures with chest compressions were greater than 15 mm Hg in both treatment groups indicating sufficient compression depth. Zero of 15 (95% confidence interval [CI] 0% to 25%) animals in the control group, 11 of 15 (73%; 95% CI 48% to 90%) in the hydroxocobalamin group, and 11 of 15 (73%; 95% CI 48% to 90%) in the epinephrine group survived to the conclusion of the study (P<.001). The proportion of animals with return of spontaneous circulation at 5 minutes was 4 of 15 (27%; 95% CI 10% to 52%), and that of return of spontaneous circulation at 10 minutes was 11 of 15 (73%; 95% CI 48% to 90%) in the 2 treatment groups. Additional epinephrine infusion after return of spontaneous circulation was administered for hypotension in 2 of 11 (18%; 95% CI 4% to 48%) hydroxocobalamin animals and in 11 of 11 (100%; 95% CI 70% to 100%) of the epinephrine animals (P<.001). At 60 minutes, serum lactate was significantly lower in the hydroxocobalamin group compared with the epinephrine group (4.9 [SD 2.2] versus 12.3 [SD 2.2] mmol/L), and the pH was significantly higher (7.34 [SD 0.03] versus 7.15 [SD 0.07]). Serial blood cyanide levels in the hydroxocobalamin group were also lower than that of the epinephrine group from cardiac arrest through the conclusion of the study.
CONCLUSION: Intravenous hydroxocobalamin and epinephrine both independently improved survival compared with saline solution control in our swine model of cyanide-induced cardiac arrest. Hydroxocobalamin improved mean arterial pressure and pH, decreased blood lactate and cyanide levels, and decreased the use of rescue epinephrine therapy compared with that in the epinephrine group.
Copyright © 2012. Published by Mosby, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22424656     DOI: 10.1016/j.annemergmed.2012.02.002

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  9 in total

1.  Cardiac Arrest Due to Cyanide Intake.

Authors:  Murat Seyit; Atakan Yilmaz; Mert Ozen; Serife Ornek; Orkun Gursoy
Journal:  Cureus       Date:  2021-01-25

2.  Antidotal Effects of the Phenothiazine Chromophore Methylene Blue Following Cyanide Intoxication.

Authors:  Philippe Haouzi; Marissa McCann; Nicole Tubbs; Annick Judenherc-Haouzi; Joseph Cheung; Frederic Bouillaud
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

3.  Revisiting the physiological effects of methylene blue as a treatment of cyanide intoxication.

Authors:  Philippe Haouzi; Maxime Gueguinou; Takashi Sonobe; Annick Judenherc-Haouzi; Nicole Tubbs; Mohamed Trebak; Joseph Cheung; Frederic Bouillaud
Journal:  Clin Toxicol (Phila)       Date:  2018-02-16       Impact factor: 4.467

4.  Intravenous cobinamide versus hydroxocobalamin for acute treatment of severe cyanide poisoning in a swine (Sus scrofa) model.

Authors:  Vikhyat S Bebarta; David A Tanen; Susan Boudreau; Maria Castaneda; Lee A Zarzabal; Toni Vargas; Gerry R Boss
Journal:  Ann Emerg Med       Date:  2014-04-18       Impact factor: 5.721

5.  On the Efficacy of Cardio-Pulmonary Resuscitation and Epinephrine Following Cyanide- and H2S Intoxication-Induced Cardiac Asystole.

Authors:  Annick Judenherc-HaouzI; Takashi Sonobe; Vikhyat S Bebarta; Philippe Haouzi
Journal:  Cardiovasc Toxicol       Date:  2018-10       Impact factor: 3.231

6.  Circulatory Failure During Noninhaled Forms of Cyanide Intoxication.

Authors:  Philippe Haouzi; Nicole Tubbs; Matthew D Rannals; Annick Judenherc-Haouzi; Larry A Cabell; Joe A McDonough; Takashi Sonobe
Journal:  Shock       Date:  2017-03       Impact factor: 3.454

7.  Antidotal effects of methylene blue against cyanide neurological toxicity: in vivo and in vitro studies.

Authors:  Philippe Haouzi; Marissa McCann; JuFang Wang; Xue-Qian Zhang; Jianliang Song; Ilker Sariyer; Diane Langford; Maryline Santerre; Nicole Tubbs; Annick Haouzi-Judenherc; Joseph Y Cheung
Journal:  Ann N Y Acad Sci       Date:  2020-05-06       Impact factor: 5.691

8.  Modest and variable efficacy of pre-exposure hydroxocobalamin and dicobalt edetate in a porcine model of acute cyanide salt poisoning.

Authors:  Adrian Thompson; Michael Dunn; Robert D Jefferson; Kosala Dissanayake; Frances Reed; Rachael Gregson; Stephen Greenhalgh; R Eddie Clutton; Peter G Blain; Simon Hl Thomas; Michael Eddleston
Journal:  Clin Toxicol (Phila)       Date:  2019-08-07       Impact factor: 4.467

9.  Azure B as a novel cyanide antidote: Preclinical in-vivo studies.

Authors:  Haouzi Philippe; McCann Marissa; Tubbs Nicole
Journal:  Toxicol Rep       Date:  2020-10-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.